scholarly journals Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up

2018 ◽  
Vol 63 (2) ◽  
pp. 217-223 ◽  
Author(s):  
CPC Sim ◽  
YL Soong ◽  
EPP Pang ◽  
C Lim ◽  
GD Walker ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated

Treatment outcomes of 257 patients with locally advanced nasopharyngeal carcinoma treated with nimotuzumab plus intensity-modulated radiotherapy with or without chemotherapy: A single institution experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6079-6079
Author(s):  
Wang Fang Zheng ◽  
Chuner Jiang
Keyword(s):  
Multivariate Analysis ◽  
Nasopharyngeal Carcinoma ◽  
Clinical Stage ◽  
Late Complication ◽  
Locally Advanced ◽  
Intensity Modulated Radiotherapy ◽  
Stage Iv ◽  
Long Term Outcome ◽  
Intensity Modulated

6079 Background: To report the long-term outcome and toxicitie of locally advanced nasopharyngeal carcinoma (NPC) treated with nimotuzumab plus intensity- modulated radiotherapy (IMRT) with or without chemotherapy. Methods: From October 2009 to March 2014, 257 newly histology-proven, non-metastatic NPC patients were retrospectively enrolled. They are aged 10-76 years. The distribution of disease was stage III in 150 (58.4%), stage IV A in 88 (34.2%), and stage IV B in 19 (7.4%). All the patients received the treatment of nimotuzumab plus IMRT, and 239 cases were used for cisplatin-based chemotherapy. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of Radiation Therapy Oncology Group. The accumulated survival was calculated according to the Kaplan-Meier method. Log-rank test was used to compare the survival difference. Multivariate analysis was performed using Cox’s proportional hazard model. Results: All patients had completed the combined treatment. With a median follow-up of 48 months (range, 13–94 months), the estimated 3-year and 5-year overall survival rates were 92.6% and 86.2%, respectively. Univariate analysis showed that age, T stage, clinical stage and neoadjvant chemotherapy were related with OS. Multivariate analysis indicated that age and clinical stage were independent prognosticators. The median cycle for nimotuzumab addition was 12 weeks. The incidence of grade 3–4 acute mucositis and leukocytopenia were 10.9% and 9.3%, respectively, with no cases of skin rash and infusion reaction. Xerostomia was the most common late complication, and the degree of dry mouth in most survivors was mild-to-moderate at the last follow-up time. Conclusions: Nimotuzumab plus IMRT with or without chemotherapy showed promising outcomes in terms of loco-regional control and survival, without increasing the incidence of radiation-related toxicities for patients.

scholarly journals Individualized Clinical Target Volume Delineation and Efficacy Analysis in Unilateral Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy (IMRT): 10-Year Summary and Results

2021 ◽  
Author(s):  
De-Huan Xie ◽  
Zheng Wu ◽  
Wang-Zhong Li ◽  
Wan-Qin Cheng ◽  
Ya-Lan Tao ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Clinical Target Volume ◽  
Parapharyngeal Space ◽  
Intensity Modulated Radiotherapy ◽  
Target Volume ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Intensity Modulated

Abstract Purpose: To evaluate the long-term local control, failure patterns, and toxicities after individualized clinical target volume (CTV) delineation in unilateral nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT).Methods: Unilateral NPC was defined as nasopharyngeal mass confined to one side of nasopharynx and did not significantly exceed the midline of nasopharyngeal apex/posterior wall. From November 2003 to December 2017, 95 patients with long-term follow-up were retrospectively included. All patients received IMRT. The CTVs were determined based on the distance from the gross tumor, the contralateral parapharyngeal space and skull base orifices were spared from irradiation.Results: There were 3 local recurrence and 8 regional recurrences in 10 patients during 84- month follow-up. All local recurrences were PGTVnx-in-field, and no recurrences in traditional high-risk area including contralateral parapharyngeal space and skull base orifices. The 10-year local-recurrence free survival, regional-recurrence free survival and overall survival were 96.2%, 90.5% and 84.7%, respectively. The dosimetry parameters of the tumor-contralateral organs were all lower than the values of the tumor-ipsilateral side (P < 0.05). The late toxicities occurred mainly in the tumor-ipsilateral organs, including radiation-induced temporal lobe injury, impaired visuality, hearing loss and subcutaneous fibrosis.Conclusion: Individualized CTV delineation in unilateral NPC could yield excellent long-term local control with limited out-of-field recurrences, reduced dose to tumor- contralateral organs and mild late toxicities, which is worthy of further exploration.

scholarly journals Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control

Cancers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 379 ◽  
Author(s):  
Sati Akbaba ◽  
Thomas Held ◽  
Kristin Lang ◽  
Tobias Forster ◽  
Philippe Federspil ◽  
...  
Keyword(s):  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Local Control ◽  
Intensity Modulated Radiotherapy ◽  
Carbon Ion ◽  
Raster Scanning ◽  
Intensity Modulated ◽  
Grade 3 ◽  
Tumor Remission

Background: In this analysis, we aimed to present the first results of carbon ion radiotherapy (CIRT), which is known for its conformal dose distribution and increased biological effectiveness in the treatment of high-risk nasopharyngeal carcinoma (NPC). Methods: We retrospectively analyzed twenty-six consecutive patients who had been treated at our center with CIRT for high-risk NPC between 2009 and 2018. Carbon ion (C12) boost was applied in a bimodal setting combined with intensity-modulated radiotherapy (IMRT) base plan. The median cumulative total dose was 74 Gy (RBE), and patients with inoperable (n = 17, 65%) or incompletely resected (n = 7, 27%) tumors were included in the analysis. Overall, 81% received concomitant chemotherapy (n = 21). Results: The median follow-up time was 40 months (range 10–97 months) for all patients. At the last follow-up, 92% of the patients were still alive. We could identify excellent tumor response with complete tumor remission (CR) in 60% (n = 15/25), partial tumor remission (PR) in 20% (n = 5/25), and stable disease (SD) in 12% (n = 3/25) of the patients according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Despite unfavorable tumor characteristics, only one patient showed a locally in-field recurrence after 56 months (4%) and another patient a locoregional recurrence in the unilateral cervical lymph nodes after 21 months (4%). The 2-year local control (LC), distant progression-free survival (DPFS), and overall survival (OS) were 95%, 93%, and 100% and the estimated 5-year LC, DPFS, and OS were 90%, 86%, and 86%, respectively. Overall, treatment was tolerated well with 20% acute and 16% chronic grade 3 side effects. No toxicity greater than grade 3 occurred. Conclusion: Bimodal radiotherapy including IMRT and active raster-scanning CIRT for high-risk nasopharyngeal cancer is a safe treatment method resulting in moderate toxicity and excellent local control. A larger patient number and longer follow-up time would be necessary to strengthen the current findings.

Sinus mucosa status in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A 5-year follow-up

Head & Neck ◽  
2015 ◽  
Vol 38 (1) ◽  
pp. 29-35 ◽  
Author(s):  
Chung-Han Hsin ◽  
Hsien-Chun Tseng ◽  
Huang-Pin Lin ◽  
Tsai-Hsin Chen
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated ◽  
Sinus Mucosa
Sign in / Sign up

Export Citation Format

Share Document